v3.26.1
Segments (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Line Items]            
Number of reportable segments | segment         1  
Research and development expenses:            
Research and development expenses $ 1,833   $ 1,541   $ 3,028 $ 3,730
General and administrative expenses:            
Stock-based compensation 387   644   774 1,079
General and administrative expenses 1,251   1,164   2,582 2,369
Loss from operations (3,084)   (2,705)   (5,610) (6,099)
Net loss (3,007) $ (2,434) (2,537) $ (3,347) (5,441) (5,884)
Reportable Segment            
Research and development expenses:            
Clinical trial expenses: 1,183   936   1,796 2,594
Contract manufacturing 49   6   82 29
Salaries and benefits related 398   292   727 622
Consulting & Other 53   44   124 62
Stock-based compensation 150   263   299 423
Research and development expenses 1,833   1,541   3,028 3,730
General and administrative expenses:            
Salaries and benefits related 310   234   591 464
Legal fees 82   74   243 243
Audit fees 69   88   158 165
Consulting 158   121   353 317
Insurance 170   160   339 316
Other 225   106   423 208
Stock-based compensation 237   381   475 656
General and administrative expenses 1,251   1,164   2,582 2,369
Loss from operations (3,084)   (2,705)   (5,610) (6,099)
Other segment items 77   168   169 215
Net loss (3,007)   (2,537)   (5,441) (5,884)
INVINCIBLE-3 Study (Phase 3 Sarcoma) | Reportable Segment            
Research and development expenses:            
Clinical trial expenses: 1,132   788   1,625 2,383
INVINCIBLE-4 Study (Phase 2 Breast) | Reportable Segment            
Research and development expenses:            
Clinical trial expenses: 51   134   169 197
Other clinical trial expenses | Reportable Segment            
Research and development expenses:            
Clinical trial expenses: $ 0   $ 14   $ 2 $ 14